Do analysts rate YDES or SVRA?

Savara has a consensus target price of $10.14, suggesting a potential upside of 81.45%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Savara 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has better earnings & valuation, YDES or SVRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Savara N/A N/A -$118.84M -$0.58 N/A

Is YDES or SVRA more profitable?

YD Bio's return on equity of 0.00% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Savara N/A -90.28% -68.95%

Do analysts recommend YDES or KURA?

Kura Oncology has a consensus target price of $25.62, suggesting a potential upside of 115.44%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kura Oncology 1 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.69

Which has better earnings and valuation, YDES or KURA?

YD Bio has higher earnings, but lower revenue than Kura Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Kura Oncology $77.23M 13.70 -$278.67M -$3.37 N/A

Is YDES or KURA more profitable?

YD Bio has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. YD Bio's return on equity of 0.00% beat Kura Oncology's return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Kura Oncology -384.30% -207.18% -45.17%

Do analysts rate SANA or YDES?

Sana Biotechnology presently has a consensus target price of $9.33, indicating a potential upside of 138.70%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Sana Biotechnology is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sana Biotechnology 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation & earnings, SANA or YDES?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A YD Bio N/A N/A N/A N/A N/A

Is SANA or YDES more profitable?

YD Bio's return on equity of 0.00% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -103.02% -39.16% YD Bio N/A N/A N/A

Do analysts rate YDES or LXRX?

Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 97.83%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lexicon Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger valuation and earnings, YDES or LXRX?

YD Bio has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Lexicon Pharmaceuticals $49.80M 20.55 -$50.34M -$0.15 N/A

Do analysts prefer YDES or FBRX?

Forte Biosciences has a consensus target price of $71.67, suggesting a potential downside of 6.83%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than YD Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score YD Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Forte Biosciences 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger valuation and earnings, YDES or FBRX?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio YD Bio N/A N/A N/A N/A N/A Forte Biosciences N/A N/A -$69.38M -$4.65 N/A

Is YDES or FBRX more profitable?

YD Bio's return on equity of 0.00% beat Forte Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets YD Bio N/A N/A N/A Forte Biosciences N/A -94.82% -77.68%

YD Bio (YDES) Competitors

$4.69 -0.10 (-2.09%)

As of 04:00 PM Eastern

Compare

YDES vs. SVRA, KURA, SANA, LXRX, and FBRX

Should you buy YD Bio stock or one of its competitors? YD Bio's main competitors and comparable companies include Savara (SVRA), Kura Oncology (KURA), Sana Biotechnology (SANA), Lexicon Pharmaceuticals (LXRX), and Forte Biosciences (FBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does YD Bio compare to Savara?

YD Bio (NASDAQ:YDES) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Savara had 6 more articles in the media than YD Bio. MarketBeat recorded 6 mentions for Savara and 0 mentions for YD Bio. YD Bio's average media sentiment score of 0.00 beat Savara's score of -0.29 indicating that YD Bio is being referred to more favorably in the media.

Company	Overall Sentiment
YD Bio	Neutral
Savara	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

YD Bio's return on equity of 0.00% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Savara	N/A	-90.28%	-68.95%

Savara has a consensus target price of $10.14, suggesting a potential upside of 81.45%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Savara beats YD Bio on 7 of the 10 factors compared between the two stocks.

How does YD Bio compare to Kura Oncology?

YD Bio (NASDAQ:YDES) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

In the previous week, Kura Oncology had 29 more articles in the media than YD Bio. MarketBeat recorded 29 mentions for Kura Oncology and 0 mentions for YD Bio. Kura Oncology's average media sentiment score of 0.61 beat YD Bio's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
YD Bio	Neutral
Kura Oncology	Positive

Kura Oncology has a consensus target price of $25.62, suggesting a potential upside of 115.44%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

YD Bio has higher earnings, but lower revenue than Kura Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Kura Oncology	$77.23M	13.70	-$278.67M	-$3.37	N/A

YD Bio has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. YD Bio's return on equity of 0.00% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Kura Oncology	-384.30%	-207.18%	-45.17%

Summary

Kura Oncology beats YD Bio on 6 of the 9 factors compared between the two stocks.

How does YD Bio compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and YD Bio (NASDAQ:YDES) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
YD Bio	N/A	N/A	N/A	N/A	N/A

In the previous week, Sana Biotechnology had 8 more articles in the media than YD Bio. MarketBeat recorded 8 mentions for Sana Biotechnology and 0 mentions for YD Bio. Sana Biotechnology's average media sentiment score of 0.16 beat YD Bio's score of 0.00 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Sana Biotechnology	Neutral
YD Bio	Neutral

88.2% of Sana Biotechnology shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

YD Bio's return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
YD Bio	N/A	N/A	N/A

Sana Biotechnology presently has a consensus target price of $9.33, indicating a potential upside of 138.70%. Given Sana Biotechnology's stronger consensus rating and higher probable upside, equities analysts plainly believe Sana Biotechnology is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Sana Biotechnology beats YD Bio on 7 of the 9 factors compared between the two stocks.

How does YD Bio compare to Lexicon Pharmaceuticals?

YD Bio (NASDAQ:YDES) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

In the previous week, Lexicon Pharmaceuticals had 2 more articles in the media than YD Bio. MarketBeat recorded 2 mentions for Lexicon Pharmaceuticals and 0 mentions for YD Bio. Lexicon Pharmaceuticals' average media sentiment score of 0.55 beat YD Bio's score of 0.00 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
YD Bio	Neutral
Lexicon Pharmaceuticals	Positive

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lexicon Pharmaceuticals has a consensus price target of $4.55, suggesting a potential upside of 97.83%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

YD Bio has higher earnings, but lower revenue than Lexicon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Lexicon Pharmaceuticals	$49.80M	20.55	-$50.34M	-$0.15	N/A

YD Bio has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. YD Bio's return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Summary

Lexicon Pharmaceuticals beats YD Bio on 8 of the 11 factors compared between the two stocks.

How does YD Bio compare to Forte Biosciences?

YD Bio (NASDAQ:YDES) and Forte Biosciences (NASDAQ:FBRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk.

Forte Biosciences has a consensus target price of $71.67, suggesting a potential downside of 6.83%. Given Forte Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Forte Biosciences is more favorable than YD Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
YD Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

YD Bio's return on equity of 0.00% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
YD Bio	N/A	N/A	N/A
Forte Biosciences	N/A	-94.82%	-77.68%

In the previous week, Forte Biosciences had 4 more articles in the media than YD Bio. MarketBeat recorded 4 mentions for Forte Biosciences and 0 mentions for YD Bio. Forte Biosciences' average media sentiment score of 0.54 beat YD Bio's score of 0.00 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
YD Bio	Neutral
Forte Biosciences	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
YD Bio	N/A	N/A	N/A	N/A	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A

77.6% of Forte Biosciences shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Forte Biosciences beats YD Bio on 7 of the 9 factors compared between the two stocks.

Get YD Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YDES and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YDES vs. The Competition

Export

Metric	YD Bio	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$332.01M	$4.00B	$7.29B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.69%
P/E Ratio	N/A	11.58	271.24	24.23
Price / Sales	N/A	1,277.41	596.63	78.04
Price / Cash	N/A	103.92	78.13	53.57
Price / Book	N/A	17.94	13.44	6.37
Net Income	N/A	-$12.50M	$3.46B	$347.74M
7 Day Performance	57.38%	3.22%	2.24%	0.08%
1 Month Performance	106.61%	6.53%	5.14%	2.13%
1 Year Performance	N/A	59.76%	27.85%	20.64%

YD Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YDES YD Bio	N/A	$4.69 -2.1%	N/A	N/A	$332.01M	N/A	N/A	N/A	Gap Down
SVRA Savara	1.8577 of 5 stars	$5.58 +3.9%	$10.14 +81.8%	+77.7%	$1.10B	N/A	N/A	20
KURA Kura Oncology	3.5454 of 5 stars	$12.53 +1.6%	$25.62 +104.4%	+66.1%	$1.10B	$67.48M	N/A	130	Insider Trade High Trading Volume
SANA Sana Biotechnology	1.823 of 5 stars	$4.10 +12.9%	$9.33 +127.6%	+7.8%	$1.09B	N/A	N/A	380	High Trading Volume
LXRX Lexicon Pharmaceuticals	1.462 of 5 stars	$2.41 -0.4%	$4.55 +88.8%	+92.9%	$1.08B	$49.80M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YDES) was last updated on 8/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

YD Bio (YDES) Competitors

YDES vs. SVRA, KURA, SANA, LXRX, and FBRX

How does YD Bio compare to Savara?

Summary

How does YD Bio compare to Kura Oncology?

Summary

How does YD Bio compare to Sana Biotechnology?

Summary

How does YD Bio compare to Lexicon Pharmaceuticals?

Summary

How does YD Bio compare to Forte Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES vs. The Competition

YD Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

YD Bio (YDES) Competitors

YDES vs. SVRA, KURA, SANA, LXRX, and FBRX

How does YD Bio compare to Savara?

Do institutionals and insiders believe in YDES or SVRA?

Does the media prefer YDES or SVRA?

Which has better earnings & valuation, YDES or SVRA?

Is YDES or SVRA more profitable?

Do analysts rate YDES or SVRA?

Summary

How does YD Bio compare to Kura Oncology?

Does the media refer more to YDES or KURA?

Do analysts recommend YDES or KURA?

Which has better earnings and valuation, YDES or KURA?

Is YDES or KURA more profitable?

Summary

How does YD Bio compare to Sana Biotechnology?

Which has better valuation & earnings, SANA or YDES?

Does the media favor SANA or YDES?

Do institutionals and insiders have more ownership in SANA or YDES?

Is SANA or YDES more profitable?

Do analysts rate SANA or YDES?

Summary

How does YD Bio compare to Lexicon Pharmaceuticals?

Does the media favor YDES or LXRX?

Do institutionals & insiders believe in YDES or LXRX?

Do analysts rate YDES or LXRX?

Which has stronger valuation and earnings, YDES or LXRX?

Is YDES or LXRX more profitable?

Summary

How does YD Bio compare to Forte Biosciences?

Do analysts prefer YDES or FBRX?

Is YDES or FBRX more profitable?

Does the media refer more to YDES or FBRX?

Which has stronger valuation and earnings, YDES or FBRX?

Do insiders & institutionals hold more shares of YDES or FBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YDES vs. The Competition

YD Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools